Bowman Acquires RPT Alliance, Broadens Energy Engineering to Include Utility-Scale Power Generation for Data Centers and Industrial Facilities High-growth acquisition adds specialized natural gas transmission and power generation engineering as electrification imperatives accelerate nationwide GlobeNewswire December 08, 2025 RESTON, Va., Dec. 08, 2025 (GLOBE NEWSWIRE) — Bowman Consulting Group Ltd. (NASDAQ: BWMN), a national engineering, […]

— C. 24 million shares to be sold Further to previous announcements, an affiliate of the funds known as EQT VIII (“EQT”) is pleased to announce it has signed an agreement to sell c. 24 million shares in Galderma Group AG (SIX: GALD) (the “Company”) to L'Oréal S.A at an undisclosed premium (the “Sale”). Out

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit againstBaxter International Inc. (“Baxter” or “the Company”) (NYSE: BAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. https://mma.prnewswire.com/media/1396534/Schall_Firm_Logo.jpg Investors who purchased

The DJS Law Group reminds investors of a class action lawsuit against WPP plc (“WPP” or “the Company”) (NYSE: WPP ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of WPP during the class

First anthrax vaccine developed using recombinant DNA technology- Annual production capacity of up to 10 million doses at GC Biopharma's facility GC Biopharma (006280.KS), a leading global biopharmaceutical company, today announced the first shipment of BARYTHRAX inj., the world's first recombinant anthrax vaccine. The product, jointly developed by the Korea Disease Control and Prevention Agency

The DJS Law Group reminds investors of a class action lawsuit against Synopsys, Inc. (“Synopsys ” or “the Company”) (NASDAQ: SNPS ) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of SNPS during the class

TheSchall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit againstSynopsys, Inc. (“Synopsys” or “the Company”) (NASDAQ: SNPS)forviolations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. https://mma.prnewswire.com/media/1396534/Schall_Firm_Logo.jpg Investors who purchased the Company's securities between

(Euronext Growth Paris:ALCLS),(NasdaqGM:CLLS), Eti-cel showed an 88% ORR and 63% CR (n=8) at current dose level in r/r NHL after greater-than or equal to2 prior lines of therapy In vivo data suggest IL-2 may further enhance response rates and optimize eti-cel expansion and persistence IL-2 cohort enrollment to start in Q1 2026; full Phase 1

(Paris:OSE), OSE Immunotherapeutics Announces Strategic Amendment to AbbVie's Partnership on ABBV-230 Development Strategic Amendment Enhances OSE Immunotherapeutics' Role in ABBV-230 Development While Preserving AbbVie's Long-Term Commitment NANTES, France, December 8th, 2025 – 7:30am CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced an amendment to its partnership agreement with AbbVie regarding ABBV-230, a

(Brussels:GLPG),(Euronext Amsterdam:GLPG), High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time Mechelen, Belgium; December 8, 2025, 07:30 CET; Galapagos NV (Euronext & NASDAQ: GLPG) announced new and updated Phase 2 data